MIRM

Mirum Pharmaceuticals, Inc.

NasdaqGMUSDEQUITY DELAYED

96.31

▼ 0.76 (0.78%)

MARKET · —

Price

Open

96.91

Prev close

97.07

Day high

97.89

Day low

95.24

Volume

685.46K

Market cap

—

P/E (TTM)

—

52W range

63.23 – 130.00

Trailing performance

Price return · vs SPY

Returnvs SPY

-4.30% -2.9%

-15.78% -19.5%

-4.33% -7.4%

-8.42% -19.5%

YTD

+21.93% +9.6%

+44.37% +24.4%

+289.92% +215.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

99.16

-2.88% from price

SMA 20

102.68

-6.21% from price

SMA 50

110.53

-12.87% from price

SMA 100

104.18

-7.56% from price

SMA 200

94.63

+1.78% from price

EMA 12

100.38

-4.05% from price

EMA 26

104.14

-7.51% from price

EMA 50

105.90

-9.06% from price

RSI (14)

37.3

Neutral

MACD (12,26,9)

-3.76

Hist -0.16

ATR (14)

4.47

4.64% of price

Realised vol 30D

51.5%

Annualised

Bollinger upper

113.66

20, 2σ

Bollinger lower

91.70

20, 2σ

50 / 200 cross

Golden

110.53 vs 94.63

Trend bias

Above 200

+1.78%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.00

Less volatile than market

Correlation to SPY

0.28

Largely independent

Realised vol 30D

51.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-26.8%

Peak to trough

Max drawdown 5Y

-40.3%

Peak to trough

ATR 14

4.47

4.64% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 96.31

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

MIRM · links out to the publisher

Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing MT Newswires · 2d ago Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next Simply Wall St. · 9d ago Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript Motley Fool · 10d ago Mirum Pharmaceuticals Insider Sold Shares Worth $1,978,402, According to a Recent SEC Filing MT Newswires · 11d ago Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · 11d ago Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath. Investor's Business Daily · 16d ago Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised Zacks · 16d ago Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15% Stocktwits · 16d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.